This stock is a great choice for cautious and aggressive investors.Investors flocked to Moderna (MRNA 4.73%) stock in the early days of the pandemic for one big reason: The company sold one of the world's most-needed products, a coronavirus vaccine. The vaccine brought in billions of dollars of revenue, and with this first product, Moderna went from a clinical-stage biotech to a highly profitable commercial-stage company in a matter of months.Though Moderna stock soared back then, in more recent times, the ...